Reclaiming Asia’s Genomic Destiny
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s…
The Korea Medical Devices Industry Association (KMDIA) is a trade association committed to improving public health and development of the industry by advocating companies that manufacture, import, export, or sell medical devices since its foundation in 1999.
The Association has around 750 members, bringing these companies together to share information and experience to disseminate the latest technologies and facilitate access to high-quality, affordable medical devices in Korea. The KMDIA is a valuable partner to government authorities such as the Ministry of Health and Welfare and the Ministry of Food and Drug Safety actively presenting policy proposals and regulation ideas, while offering extensive support to Korean medical devices manufacturers compete and grow further in the global market.
The medical devices industry continues rapid growth despite economic slowdown across the world. The factors that drive such growth include: aging society, growing anti-aging industry as a result of higher income, greater interest in health and wellness, government policies that value higher standard of life, emerging latest technologies and biomedical innovation. The Korean government designated the medical devices industry as one of its priority “growth engines” aspiring to lift Korea to global top 5 in the industry by 2018.
The Association also supports foreign and multi-national medical devices companies by providing market intelligence and statistics while assisting them in regulatory and approval procedures. Local and foreign firms are brought together to enter into business discussion and invited to exhibitions hosted by the KMDIA. The MOUs with the counterparts in different regions, such as AdvaMed and EucoMed, are part of the efforts to build networks and promote interactions among member companies, to eventually promote Korea as an attractive market.
The KMDIA is a dedicated partner to all members who seek assistance and partnership.
Contact details:
8~9F, Yeosam Bldg, 123 Teheran-ro, Gangnam-gu, Seoul Korea (135-748)
Tel: +82 2 596 7404
Fax: +82 2 596 7401
kmdia@kmdia.or.kr
www.kmdia.or.kr
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s…
Dr Jeong-Sun Seo, chairman of Macrogen & president of the Korea Biotechnology Industry Organization (KoreaBIO), explains the basis for Korea’s success in combating the spread of COVID-19, casts light on…
Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae Cho, discusses the importance of creating a test tailored to Asian…
Yeul-Hong Kim, Director of K-MASTER details the project’s success in creating a shared database of genomic data for Korean oncology professionals. Kim also explains the importance of collaboration with Big…
Korean biosimilar firm Celltrion’s USD 266 million acquisition of Japanese outfit Takeda assets in the Asia-Pacific region marks a significant moment in Celltrion’s international expansion as well as yet another…
Under the stewardship of regenerative medicine industry veteran BG Rhee, Korean firm SCM Lifescience has engaged in several global M&A deals in the past year with the end goal of…
Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr Jisoo Pae, its co-founder and CEO, sat down with PharmaBoardroom to…
After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the US market and an Investigational New Drug (IND)…
Kyung Suk Kim, CEO of Corestem, the first company to receive approval for a stem cell therapy for Amyotrophic Lateral Sclerosis (ALS) in Korea, recounts the firm’s main achievements since…
With over 30 years of experience in public office working in public health and pharmaceutical policy, food and drug safety regulations, national health and welfare policy, and overseas missions as…
Dr Bae Byuongjun, president of the Korea National Enterprise for Clinical Trials (KoNECT), outlines why Korea stands out in the APAC region as a top clinical trial destination, how clinical…
Founder, CEO and CTO Dr Chae-Ok Yun introduces GeneMedicine, a pioneer of the oncolytic virus approach in gene therapy. Dr Yun outlines the significance of a recent capital injection, ongoing…
See our Cookie Privacy Policy Here
